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Abstract
Hedgehog (Hh) signaling promotes tumorigenesis. The accumulation of a membrane protein
Smoothened (Smo) within the primary cilium (PC) is a key event in Hh signal transduction and
many pharmacological inhibitors identified to date target Smo’s actions. Smo ciliary translocation
is inhibited by some pathway antagonists while others promote ciliary accumulation; an outcome
that can lead to a hypersensitive state on renewal of Hh signaling. To identify novel inhibitory
compounds acting on the critical mechanistic transition of Smo accumulation, we established a
high content screen to directly analyze Smo ciliary translocation. Screening thousands of
compounds from annotated libraries of approved drugs and other agents, we identified several new
classes of compounds that block Sonic hedgehog-driven Smo localization within the PC. Selective
analysis was conducted on two classes of Smo antagonists. One of these, DY131, appears to
inhibit Smo signaling through a common binding site shared by previously reported Smo agonists
and antagonists. Antagonism by this class of compound is competed by high doses of Smo-
binding agonists such as SAG, and impaired by a mutation that generates a ligand independent,
oncogenic form of Smo (SmoM2). In contrast, a second antagonist of Smo accumulation within
the PC, SMANT, was less sensitive to SAG-mediated competition, and inhibited SmoM2 at
similar concentrations to those that inhibit wild-type Smo. Our observations identify important
differences among Hh antagonists and the potential for development of novel therapeutic
approaches against mutant forms of Smo that are resistant to current therapeutic strategies.
Hedgehog (Hh) signaling plays an essential role in developmental processes and adult tissue
homeostasis (1). An increasing body of evidence identifies the Hh pathway as a contributing
factor in the growth of a variety of human cancers. The loss of normal regulatory control of
the Hh pathway within a subset of Hh responsive cells leads directly to the initiation of
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particular solid tumors, notably basal cell carcinoma (BCC), the most prevalent cancer in the
Caucasian population (2), and medulloblastoma (MB), the most common childhood brain
cancer (3). In other cancers, Hh signals from tumor cells appear to condition the local
environment to favor tumor growth. This category includes a broad spectrum of high
incidence cancers, particularlythose in breast, lung, liver, stomach, pancreas, prostate, and
gastro-intestinal tract (4–5). The potential of Hh targeted cancer therapy has stimulated an
extensive search for Hh pathway antagonists. Typically, drug discovery screens have
broadly sampled the Hh pathway looking for agents capable of silencing a Hh signal-
dependent transcriptional response. Although small-molecule “hits” may occur at any point
in the pathway that can ultimately translate into an altered transcriptional response,
Smoothened (Smo), has emerged as the prevalent target. (6–7) Smo is essential for all
pathway activity, and activating mutations in Smo have been observed in both human BCC
and MB. Smo antagonists have entered clinical trials (8), andsuccessful repression of
tumorigenesis in patients with invasive or metastatic forms of BCC has validated the
concept of Hh targeted cancer therapy (9). The leading drug, GDC0449 (now marketed as
Erivedge), was recently approved by the US Food and Drug Administration (FDA) for
treatment of advanced BCC (10)(10)(10).
An obligatory step in the activation of Hh signaling is the accumulation of Smo in the
primary cilium (PC), a tubulin-scaffolded membrane extension templated by the centriole
(Supplementary Fig. 1). While all small molecule Smo agonists examined so far induce Smo
accumulation in the PC, various Smo antagonists affect Smo localization in distinct ways
(Supplementary Fig. 1) (11–13). SANT-1, SANT-2, and GDC0449 inhibit both Hh pathway
activation and Sonic hedgehog (Shh) induced Smo accumulation within the PC (11–13). In
contrast, Cyclopamine (cyc), a natural product from the plant Veratrum californicum, and its
potent derivative KAAD-cyc, bind Smo and inhibit pathway activation, but behave as
pseudo-agonists promoting Smo accumulation within the PC (11–14). Further, forskolin
(FKL), a putative protein kinase A (PKA) activator, inhibits Hh pathway activity and
indirectly promotes Smo ciliary accumulation through PKA stimulation (11). Thus, there are
distinct actions and outcomes associated with different inhibitory factors grouped around
Smo action (Supplementary Fig. 1). To explore regulatory activity at this critical level of
pathway action, we performed a direct screen for inhibitors of Smo translocation to the PC
and identified 20 classes of inhibitory compounds. We identified some novel compounds
that may act on Smo in a similar manner to previously identified antagonists and agonists,
underscoring the chemical diversity of compound interactions at what is possibly a common
site. However, we also identified a new compound, SMANT, which inhibits an oncogenic
form of Smo refractory to inhibition by currently available Smo antagonists.
Results
Screening for antagonists of Smo translocation to the primary cilium
In work to be published elsewhere, we have established a high content screen for modulators
of Smo translocation focusing on small molecules stimulating Smo translocation to the PC
(Wang Y. et al., under revision). We then modified the system to identify inhibitors of Smo
ciliary translocation. In brief, we developed a cell line producing human Smo::EGFP and
Ivs::tagRFPT fusion proteins. Ivs::tagRFPT highlights the PC, and GFP enables the cellular
trafficking of Smo to be visualized. Test compounds were added in low serum medium for
18–24 hours in the presence of Shh, cells were then fixed and stained with Hoechst
(Supplementary Fig. 2). Quantitative multi-parametric image analyses were performed with
custom algorithms (For details, please refer to Materials and Methods). The most critical
parameters measured are indicated in Fig. 1a: Cell number was measured by counting
Hoechst-labeled nuclei whereas the PC was precisely segmented as an Ivs::tagRFPT positive
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structure; the specific PC localization of Smo::EGFP was discerned by applying a defined
threshold for the length-width ratio of Ivs::tagRFPT positive structures (inset in
Ivs::tagRFPT images) and then quantifying hSmo::EGFP intensity within the Ivs::tagRFPT
positive PC. Key measurements from these analyses are shown for GDC0449 (Fig. 1b and c)
and SANT-1 (Supplementary Fig. 3). As expected, each specifically inhibited Smo::EGFP
accumulation in the PC without causing significant structural changes to the PC itself or
measurable cytotoxicity (15–16).
We used this high content assay to screen a collection of approximately 5,600 small
molecules for compounds that block Smo accumulation in the presence of Shh. The small
molecule library includes FDA approved drugs, drug candidatesin preclinical or clinical
development and a group of compounds with annotated biological activity. Representative
examples of assay plates are shown (Supplementary Fig. 4). Z-prime scores (17) were
consistently >0.6, confirming the robustnessof the screen.
We first eliminated small molecules with “off-target” effects, e.g. inhibitory effects on
ciliary assembly/trafficking or general cytotoxicity. For example, HPI-4, a molecule that
leads to truncation or loss of the PC (18), and vinblastine, a drug known to disrupt the
assembly of microtubules (19), both appear as Hh pathway antagonists in a Gli-luciferase
reporter assay (Fig. 2 a and c). However, the decrease in the Ivs::tagRFPT ciliary signal in
the Smo high-content assay indicates a non-specific mechanism that alters PC structure (Fig.
2).
We identified 26 validated hits that could be divided into 20 classes. These hits include
known Hh pathway inhibitors such as AntagVIII, a potent phenyl quinazolinone urea
derivative (Supplementary Fig. 5)(20). Moreover, identification of AY9944, an inhibitor of
cholesterol biosynthesis and esterification (21), adds additional support to the proposed
intersection between cholesterol metabolism and the Hh pathway26. Hh ligands are
covalently modified by cholesterol27 and Hh trafficking has been linked to cholesterol
transport processes (22–23),29 but in vitro studies suggest the response of the target cell is
actually suppressed when cholesterol biosynthesis is blocked (24). Our data suggest a
potential link with Smo accumulation within the PC (Supplementary Fig. 6). Further, in line
with a recent report (25), our screen identified itraconazole and ketoconazole, two anti-
fungal drugs in current clinical use, as Smo inhibitors in the ciliary-based assay
(Supplementary Fig. 7). In all cases examined, compounds that blocked Smo translocation to
the PC inhibited Gli transcription activity (Supplementary Figs 5–7).
DY131 inhibits Smo signaling through a conventional mechanism
Of the novel compounds, we first selected DY131, a potent hit, for subsequent analysis.
DY131, and its analog GSK4716, inhibited Shh induced accumulation of Smo::EGFP with
IC50’s of 0.8 μM and 2μM respectively (Fig. 3a–c, Supplementary Fig. 8, Table 1). Both
DY131 and GSK4716 inhibit Shh induced activation of a Glireporter with somewhat higher
IC50’s (2μM and 10μM respectively) (Fig. 3d). The absence of an inhibitory activity in a
Wnt pathway reporter assay argues for a specific action of DY131 in suppressing Shh action
(Supplementary Fig. 9).
DY131 and GSK4716 were previously identified as agonists of the estrogen related
receptors (ERR) (26–27). However, other ERR/ER ligands, including tamoxifen citrate, 4-
hydroxytamoxifen (4-OHT), diethylstilbestrol, and hexestrol, did not alter the accumulation
of Smo on the PC in either the presence or absence of Shh (Supplementary Fig. 10), arguing
against an ERR-based mode of action for DY131 and GSK4716.
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To investigate at what level DY131 functions in the Hh pathway, we compared the drug’s
dose-dependent performance in inhibiting the activities of wild-type Smo and SmoM2 (also
named SMOA1), a constitutively active form of Smo with a tryptophan to leucine mutation
in the 7th transmembrane domain (2). This mutation renders Smo markedly less sensitive
(IC50’s for SmoM2 are more than an order of magnitude higher than IC50’s for wildtype
Smo) to Cyc, SANT-1 and GDC0449-mediated inhibition (15–16, 28) (Supplementary Figs
11–12). When over-expressed, both wild-type Smo and SmoM2 constitutively localize to the
primary cilium (6, 29). In contrast to its potent inhibition of the ciliary accumulation of wild-
type Smo following exposure to Hh ligand (Fig. 3c), or over-expression of wild-type Smo
(Fig. 3 e and f), DY131 failed to inhibit ciliary localization of SmoM2, or SmoM2 driven
activation of transcriptional reporters of pathway activity, at doses up to 30μM (Fig. 3 e–g).
However, DY131 suppressed SAG (100nM) induced accumulation of Smo::EGFP in the
primary cilium and Gli transcription activity with an IC50 of approximately 2μM
(Supplementary Fig. 13).
Interestingly, SANT-1 and GDC0449, at a dose high enough to block SmoM2 activity, did
not alter SmoM2 ciliary accumulation, suggesting that, as with wild-type Smo, activity of
this mutant can be abolished without blocking its localization to the PC (Supplementary Figs
11).
To determine if DY131 binds directly to Smo, we used a competition assay with bodipy-
Cyc, a fluorescent analog of Cyc (30). Bodipy-Cyc specifically labels cells over-expressing
Smo, co-expressing a red, nuclear fluorescent protein (Nuc-tagRFPT) marker, whereas
SmoM2-expressing cells do not bind bodipy-Cyc, confirming the specificity of this assay
(Fig. 3 h and i). DY131, like Cyc and SANT-1, acts as an effective competitor of bodipy-
Cyc labeling of cells overexpressing Smo, consistent with either direct binding to Smo at the
same site as bodipy-Cyc, or at another site on Smo resulting in allosteric modification and
loss of bodipy-Cyc binding (Fig. 3 h and i).
SMANT inhibits Smo signaling with a novel mechanism
Our data suggest that DY131 and its analogs inhibit Hh signaling through a similar
mechanism to inhibitors such as Cyc, SANT-1, and GDC0449. However, our focused effort
in characterizing most potent hits from the screen also identified small molecules displaying
novel behaviors. We named one compound, Smo Mutant ANTagonist (SMANT) as it
exhibited an equivalent activity in inhibiting SmoM2 and wild-type Smo (Fig. 4a and h).
SMANT and its analog SMANT-2 inhibited Shh induced ciliary accumulation of
Smo::EGFP with IC50’s of 1.1μM and 1.6μM, respectively (Fig. 4b and c; Table 1). Neither
resulted in altered Ivs::tagRFPT localization at the PC or profound modulation of Wnt
pathway activity consistent with a Hh pathway specific mode of action (Fig. 4b;
Supplementary Fig. 14 and 15).
As with DY131, SANT-1, and GDC0449 (Fig. 3e and f, Supplementary Fig. 11), SMANT
failed to block SmoM2::EGFP localization to the PC while potently inhibiting wild-type
Smo accumulation (Fig. 4d and e). In contrast to some of the other Smo antagonists,
SMANT failed to block Smo ciliary localization induced by SAG or Cyc (Fig. 4f and g;
Supplementary Fig. 16; Supplementary Fig. 13a and b). However, in contrast to other
pathway inhibitors, SMANT was similarly effective at inhibiting Smo and SmoM2 activity,
and blocked the stimulatory action of SAG at different concentrations in the Gli-luciferase
assay (Fig. 3d, 3g and 4h; Supplementary Fig. 12 and 13c). SMANT, like DY131 and
GDC0449, and distinct from GANT61 (31), a known Gli inhibitor, does not alter Hh
pathway activation induced by loss of suFU, a Gli regulatory factor (Fig. 4i), suggesting that
SMANT functions at the Smo level. However, in contrast with strong competition between
Wang et al. Page 4
ACS Chem Biol. Author manuscript; available in PMC 2014 January 29.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
DY131 and Cyc for binding Smo (Fig. 3h and i), SMANT was a poor competitor (Fig. 4j
and k), consistent with a unique inhibitory action on Smo activity.
DY131 and SMANT effectively inhibit Hh signaling without the risk of rebound
hyperactivity
To further explore the potential utility of compounds found in our assay for developing anti-
cancer agents for Hh pathway targeted therapies, we tested DY131 and SMANT on cultured
cerebellar granule neuron precursors (CGNPs) isolated from Ptch1+/− neonates.
Constitutive activation of Hh signaling in these cells is associated with medulloblastoma
(32). Consistent with their potency in inhibiting Hh activity in NIH/3T3 cells, DY131 and
SMANT dramatically decreased phosphorylated histone H3 (pH3) marked proliferation of
CGNPs induced by Shh (Fig. 5 a–b).
Finally, we primed cells with GDC0449, Cyc, FKL or SANT-1 at doses sufficient to
decrease both Smo ciliary localization and Gli mediated transcription activity for 24 hours
(Supplementary Fig. 1). Following the removal of drug containing medium, and extensive
washing, cells were stimulated with either Hh ligand, or the direct-binding Smo agonist
SAG (16, 33). As predicted, we observed an elevated signaling response specifically in Cyc
and FKL treated cells (Supplementary Fig. 17a, Supplementary Fig. 18). The
hypersensitivity to Hh pathway activation correlated with high levels of Smo that remained
within the PC following removal of the antagonizing compound (Supplementary Fig. 17b–
e). Next we tested the consequences of this effect for newly identified DY131 and SMANT
using NIH3T3 cells (Fig. 5c) and CGNPs (Fig. 5 d–e). In contrast to Cyc, we observed no
Shh driven hyperactivation of Hh pathway activity on removal of DY131 or SMANT in
either the NIH3T3 Gliluciferase assay or the CGNP proliferation assay.
Discussion
Based on evidence presented here, compounds that inhibit both pathway activity and Smo
accumulation in the primary cilium have characteristics that may make them reasonably
preferred to antagonists that themselves promote ciliary accumulation of Smo. Therefore,
the type of high content screen that we have established, which directly quantifies the Smo-
PC interactions required for Hh pathway activity, is useful both for discovering new classes
of antagonists, as well as for studying existing ones. The current screen, of over 5,000
compounds, selectively identified a substantial number of small molecules with efficacy in
this assay, and more conventional Hh pathway assays. While careful analysis of DY131
suggests a direct interaction with Smo, SMANT shows a unique profile inhibiting an
oncogenic form of Smo carrying the M2 mutation with similar efficacy to its wild-type
counterpart. The differing properties of SMANT when compared with a variety of other
Smo modulators (SAG, Cyc, GDC0449, and SANT-1) are consistent with a SMANT
inhibitory action at a different site on Smo to that bound by these other compounds, or an
indirect modulation of Smo activity. Smo can be inactivated in the PC by SMANT when
harboring the M2 mutation, or after SAG driven translocation to the PC, suggesting that
SMANT may inactivate both the oncogenic form and an SAG-bound form of Smo, and
more importantly, the ciliary localization of Smo and its activation may be mechanistically
divergent. It is possible that post-translational modifications, conformation changes, or
interacting partners that regulate ciliary entry or accumulation of Smo differ from those
governing activity in the primary cilium.(34–35) Frequently, compounds show a higher
potency in the inhibition of Smo localization to the primary cilium than that in Gli-luciferase
assays (Fig. 3c and d, Fig. 4 c and h, Supplementary Fig. 5–7). This could reflect pathway
activity while Smo is out of the PC, or the different time frames involved in the two assay
systems.
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Our studies highlight new opportunities for therapeutic development that may potentiate
existing approaches and over new strategies towards treatment of resistant forms of Smo
emerging from somatic mutation. The screening platform provides a robust assay system.
The Smo ciliary screen broadly interrogates a key aspect of HH pathway regulation and
biology, and potentially identifies small molecule regulators that may not score in a
conventional transcriptional end-point assay. These compounds may nevertheless provide a
reasonable grounding for subsequent drug development. Further, the screen enables a
stratification of small molecule function in the HH pathway and a platform that can be
extended to potentially explore ciliopathies, an increasingly important area of medical
significance (36).
Materials and Methods
Cell Culture
NIH/3T3 cells were maintained in DMEM containing 10%(v/v) calf serum, penicillin,
streptomycin, and L-glutamine. HEK293, L, cos7, and suFU−/− mouse embryonic fibroblast
cells were maintained in DMEM containing 10%(v/v) fetal bovine serum, penicillin,
streptomycin, and L-glutamine. Smo::EGFP, SmoM2::GFP, and Ivs::tagRFPT were cloned
into pBabe to generate retroviral particles for infection. Smo::EGFP/Ivs::tagRFPT and
SmoM2::GFP/Ivs::tagRFPT stable cell lines were generated through viral infection of NIH/
3T3 (13). A ShhLightII Gli reporter cell line was obtained from the American Type Culture
Collection (ATCC) and used in luciferase reporter assays to measure Hh pathway activity.
The cell line contains a stably integrated Gli-responsive Firefly luciferase reporter and a
constitutive Renilla luciferase expression construct (28). Subclones expressing Smo or
SmoM2 in ShhLightII cells were used for chemical epistasis analyses.
Shh conditioned medium, which is collected from cos7 cells transfected with an expression
construct encoding the amino terminal 19kDa signaling peptide of Shh, was used at 13.7
(±3.0) nM. Wnt3a conditioned medium was collected from an L-cell line producingWnt3a
ligand (37). Controls utilized supernatants from cells cos7 cells transfected with empty
vector or a wild-type L-cell line.
Reagents
Cyclopamine and forskolin were purchased from Sigma. SAG, SANT-1, GDC0449, and
BODIPY-cyclopamine were purchased from Axxora Platform, Tocris Biosciences, Selleck
Chemicals, and Toronto Research Chemicals, respectively. All small molecule stock
solutions were prepared by dissolving in DMSO at 10 mM and stored at −20°C. Mouse
recombinant ShhN purified protein (IIShhN) was purchased from R&D Systems.
Transfection was performed using Fugene 6 or Fugene HD from Roche.
Imaging Assays
Cells were cultured and treated in 384-well imaging plate precoated with poly-D-Lysine
(Greiner Bio-one), fixed with 4%(w/v) paraformaldehyde (Electron Microscopy Sciences),
and stained with Hoechst (Invitrogen). Images were collected using Opera High Content
Screening System (Perkin Elmer). Activity Base (IDBS Inc,) and Pipeline Pilot (Accelrys,
Inc.) were used for high content screening data management and analysis.
Image Analysis of Smo Ciliary Localization
Acapella 2.0 software (Evotec Technologies/PerkinElmer) was used to perform multi-
parametric high content image quantification. Our image analysis script used Ivs::tagRFPT
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to first determine the location of the PC and then Smo::EGFP to quantify the level of Smo
present in the cilium.
First, we used the spot-finding algorithm in the RFP channel to find Ivs-rich spots. Each
non-overlapping spot was based on a maximum 8 pixel-radius (when using a 40x objective)
around a central intensity peak of 5 pixels. A distance of at least 10 pixels was required
between adjacent spot centers. Spot peaks had to exceed thresholds of relative intensity
compared to the remaining body of the spot as well as to the entire image. The average,
maximum and total RFP intensity of each spot were measured. The spots with sufficiently
high absolute maxima to pass the selected threshold were classified as positive spots. To
form candidate cilia, we selected the brightest 15% of the pixels in each positive spot and
merged those pixels into objects so that the brightest parts of adjacent spots could form
single, larger cilia-shaped objects. To qualify the candidate cilia as true Ivs-positive cilia, the
width of the objects created from merging the brightest pixels in each spot had to be at least
2 pixels and the length to half-width ratio had to exceed 3. (i.e. a 3-pixel long by 2-pixel
wide cilium was the minimum accepted cilium size and the length had to be at least 1.5 fold
of the width). The mean GFP intensity within these Ivs-positive cilia was used to estimate
the ciliary level of Smo protein. We found it necessary to subtract the background of the
mean GFP intensity in the 3-pixel wide area around each candidate cilium to avoid some
false positives. Those Ivs-positive cilia that exceed the final mean GFP intensity threshold
set for each experiment were deemed Smo-positive cilia.
Hoechst staining was used to determine the total number of nuclei per well. The final output
measurements of the number of Ivs-positive cilia in the well, the number of Smo-positive
cilia in the well and the mean GFP intensity of the accepted cilia within the well were used
to calculate if a compound qualified as an inhibitor and to estimate the quality of inhibition.
Inhibitors of smoothened accumulation into the cilia were initially chosen as compounds
that had numbers of Ivs-positive cilia per nucleus (or per field of view) similar to the DMSO
controls, but fewer Smo-positive cilia compared to the DMSO controls. Compounds that
generated many fewer Ivs-positive cilia were judged as either defective in cilium assembly/
trafficking or generally toxic depending on the morphology of the cells. Measurements of
the geometry of the cilia as well as the total fluorescent intensities of each cilium in the
Smo- and Ivs- channels were used to determine if any of the compounds were having
unusual effects on cilia size, intensity or frequency of observation or combinations of all
three characteristics.
The thresholds and parameters used in selecting, classifying, and quantitating spots,
candidate cilia and nuclei, were applied uniformly for every well in each set of plates
prepared as a single batch with the same set of cells and reagents. We used diagnostic
images during threshold selection to outline which objects (spots, candidate cilia, candidate
nuclei etc) passed or failed each selection. At least 2 fields of positive controls (Shh
+SANT-1) and negative controls (Shh+DMSO) were examined for threshold setting. Visual
observation and Z-prime calculations measuring the ability of the assay to distinguish
positive from negative controls were used for quality control on each batch of plates and set
of thresholds. All the images for comparison were scanned with identical microscopic
settings and analyzed with the same input parameters.
Hh and Wnt activity assays
Hh activity assays were performed using ShhLightII cells, Smo/LightII cells, SmoM2/
LightII cells, and suFU−/− mouse embryonic fibroblasts. In the suFU−/− cells, Hh activity
was measured after co-transfection with Gli driven firefly luciferase and TK-renilla
luciferase reporters (38). Wnt activity was measured in 293 cells co-transfected with Top-
flash and TK-renilla luciferase reporters (39). Cells were cultured and treated in 96 well
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assay plates (Corning) and incubated with Duo-Glo luciferase substrates (Promega) to
measure firefly and renilla luciferase activity sequentially using a TopCount NX Microplate
Scintillation and Luminescence Counter (Perkin Elmer). The renilla luciferase signal was
used to normalize the firefly reporter activity.
Bodipy-Cyclopamine Competition Assays
Cos7 cells were transfected with a plasmid co-expressing Smo and a nuclear localized form
of tagRFPT (pCIT-Smo). An empty parental construct (pCIT), and a construct that co-
expresses SmoM2, were used as controls to assess specificity and background noise. Three
days after transfection, cells were incubated with 5 nM Bodipy-cyclopamine, with or
without other compounds for 1 hour at 37°C. Cells were washed, fixed and stained with
Hoechst. Images were collected by an Opera High Content Screen System. Bodipy
fluorescence was quantified specifically for transfected cells (determined by red tagRFPT+
nucleus) using a program developed by the authors with Acapella 2.0 software. All of the
images were scanned with identical microscopic settings and analyzed with the same input
parameters.
CGNP proliferation Assays
CGNP primary cells were isolated from P7 Ptch1+/− mice as previously reported (40) and
immediately seeded in poly-D-lysine coated imaging plates (Greiner Bio-one). Compounds
were applied 2 hours post seeding, for either 36 (Fig. 5a–b) or 72 hours (Fig. 5d–e). After
completion of each experimental regimen, cells were fixed with 4% paraformaldehyde
(Electron Microscopy Sciences), and stained with anti-pH3 antibody (Upstate; 1:100)
followed by a secondary antibody (Invitrogen) and Hoechst (Invitrogen). Images were then
collected using a confocal microscope. Cell proliferation, as marked by a pH3 signal, was
quantified with an in-house program developed by the authors using Acapella 2.0 software.
Identical microscopic settings were used in each analysis and identical input parameters
were implemented for each experiment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1.
A high content Smo antagonist screen - image analysis and assay validation.(a) A field of
cells in a typical well. The cell number was calculated by counting Hoechst stained nuclei.
The PC were precisely segmented as Ivs::tagRFPT positive structures and hSmo::EGFP
intensity was quantified in the PC. (b) Representative images of the dose-dependent
inhibition of Smo::EGFP ciliary accumulation by GDC0449. The concentrations of
GDC0449 used to obtain these images were 0, 0.15nM, 1.3nM, 12nM, 111nM, 1μM from
left to right. Scale bar: 10μm. (c) Key measurements from high content image analyses. The
cell number was determined by counting Hoechst stained nuclei. Ivs::tagRFPT positive
structures were precisely segmented as the PC and Smo::EGFP intensity within the PC was
quantified. The Ivs+ cilium count and Smo+ cilium count were determined based on
arbitrary thresholds; the mean (±S.D) shown is based on four replicates.
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Fig. 2.
Identification of compounds disrupting the PC. (a–b) HPI-4, an inhibitor of ciliogenesis,
was identified in the assay. Please note that, throughout this paper, Ctrl% is an additional
normalization over the mean of DMSO (with or without Shh) treatment as 100%, unless
stated otherwise, such as “Ctl=1”.(c–d) Vinblastine (VBN), which disrupts microtubules,
and leads to disruption of the PC, was also identified through general effects on
Ivs::tagRFPt; the mean (±S.D) for the Smo localization assay and Gli-luciferase
transcriptional reporter assays was calculated from four replicates (a and c). HPI-4 and VBN
were used at 50μM and 370nM, respectively, to generate the representative images in (b)
and (d). Scale bar: 10μm.
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Fig. 3.
DY131 displays a conserved mechanism for Smo inhibition similar with previously
identified antagonists. (a) Structure of DY131 and GSK4716. (b–c) Representative images
(b) and quantification (c) of DY131 and GSK4716 inhibition of Hh induced Smo
accumulation at the primary cilium. 500nM SANT-1 was used as a positive controlfor
pronounced inhibition. DY131 and GSK4716 were used at 3.75μM and 7.5μM, respectively,
for data in (b). Scale bar: 5μm. (d) Gli-luciferase measurements indicate dose-dependent
inhibition of Hh pathway activity by both DY131 and GSK4716. Data show the means
(±S.D.) from quadruplicate samples. Image analysis was based on over 300 cells per sample.
(e) Representative images showing Smo::EGFP and SmoM2::EGFP overexpressing cells
treated with vehicle or 1.1μM DY131. Scale bar: 5μm. (f) Image analysis of quadruplicate
samples, plotting mean (±S.D.) of over 300 cells analyzed in each sample. (g) Dose-
response curves displaying DY131 inhibition of wild-type Smo, and SmoM2 activity. Data
show mean (±S.D.) in quadruplicate samples. Representative images (h) and quantification
(i) of Bodipy-Cyc competition experiments. Cyc, SANT-1, and DY131 were each used at
1.1 μM in (h). Scale bar: 10μm. Data show the mean (±S.D.) in quadruplicate samples (i),
analyzing 50–100 transfected cells in each sample.
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Fig. 4.
SMANT displays an unprecedented mechanism for Smo inhibition. (a) Structure of SMANT
and SMANT-2. (b–c) Representative images (b) and quantification (c) of SMANT and
SMANT-2 inhibition of Hh induced Smo accumulation at the primary cilium. 1μM SANT-2
was used as a positive control. SMANT and SMANT-2 were used at 7.5μM for data in (b).
Scale bar: 5μm. (d) Representative images showing Smo::EGFP and SmoM2::EGFP
overexpressing cells treated with vehicle or SMANT. SMANT was applied to wild-type
Smo and SmoM2 expressing cells at 7.5μM and 30μM respectively. Scale bar: 5μm. (e)
Image analysis of quadruplicate samples shown in (d), plotting mean (±S.D.) of over 300
cells analyzed in each sample. (f–g) Representative images (f) and quantifications of
Smociliary localization (g) showing Smo::EGFP/Ivs::tagRFPT cells treated with 100nM
SAG combined with vehicle, SANT-1, GDC0449, or SMANT. SANT-1, GDC0449 and
SMANT were used at 1μM, 120nM, and 60μM. (h) Gli-luciferase measurement of dose-
dependent inhibition of Hh pathway activity by SMANT upon Shh stimulation,
overexpression of Smo and SmoM2 respectively, or treatment with 0.2 μM or 1μM of SAG.
Data show the means (±S.D.) from triplicate samples. (i) Gli-luciferase measurements in
suFU−/− mouse embryonic fibroblasts treated with DY131 and SMANT respectively.
GDC0449 and GANT61 were used as negative and positive controls respectively. (j–k)
Representative images (j) and quantification (k) of Bodipy-Cyc competition experiments for
SMANT. SANT-1 served as a control for competition activity. SMANT was used at 30 μM
in (h). Scale bar: 5μm. Data show the mean (±S.D.) from quadruplicate samples (i),
analyzing 100–200 transfected cells in each sample.
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Fig. 5.
DY131 and SMANT inhibit proliferation of cerebellar granule-cell neural progenitors
(CGNP) without conferring hypersensitivity to Shh stimulation. (a–b) representative images
(a) and quantification of phospho-histone H3 (pH3) positive cells (b) upon co-treatment with
0.625μM DY131 or SMANT with Shh ligand. (b) P<=0.001 in t-test for all samples treated
with DY131 or SMANT at 0.625μM and above compared with DMSO treated controls. (c–
e) In contrast to Cyc, GDC0449, DY131, and SMANT do not confer prolonged
hypersensitivity to Shh stimulation in either Gli responsive reporter (c) or CGNP
proliferation assays (d–e). Hh signaling activity and CGNP proliferation were measured
after treatment with vehicle, Cyc (5μM), GDC0449 (500nM), DY131 (10μM), or SMANT
(10μM) separately. Samples were analyzed in quadruplicate; data show the mean (±S.D.).
For the Gli-luciferase reporter assay (c), cells stimulated by Shh for a relatively short time
period (12 hours) displayed a modest but significant inductive response (#p<0.003 in a t test
comparing to a DMSO primed 0 nM Shh treatment). The response was enhanced by pre-
treating cells with Cyc (##P<0.003 in t test comparing to DMSO priming and stimulation
with the same concentration of Shh) whereas pretreatment with GDC0449, DY131, or
SMANT showed no enhancing activity (P>0.05 in t test comparing samples primed with
DMSO and stimulated with the same concentration of Shh). For the CGNP assay (d–e), cells
were treated for 3 days. +p<0.0001 in a t test comparing the effects of DMSO (control) or
any of the antagonists of Smo ciliary accumulation.
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Table 1
IC50’s of newly identified Smo antagonists in various cell based assays. Please note that IC50’s in this paper
were obtained through non-linear regression based on the following equation:
, where the top and bottom are the Y values of
plateaus of no inhibition and saturated inhibition separately.
Cell Line Stimulus Measurement DY131 SMANT
3T3/Smo::GFP/Ivs::tagRFPT Shh Inhibition of Shh-induced Smo::GFP
ciliary accumulation
0.8 1.1
3T3/Shh-LightII Shh Inhibition of Shh-induced expression
of Gli-luciferase reporter
2 2
3T3/Smo::GFP/Ivs::tagRFPT SAG Inhibition of SAG-induced Smo::GFP
ciliary accumulation
2 (100nM SAG) >60 (100 nM
SAG)
3T3/Shh-LightII SAG Inhibition of SAG-induced expression
of Gli-luciferase reporter
2 (100nM SAG) 3 (200n M
SAG); 4 (1
μM SAG)
3T3/Smo::GFP Overexpression/Ivs::tagRFPT None Inhibition of ciliary accumulation of
Smo::GFP upon overexpression
0.08 3
3T3/Smo::GFP Overexpression/Shh-LightII None Inhibition of expression of Gli-
luciferase reporter induced by
Smo::GFP overexpression
>30 3
3T3/SmoM2::GFP Overexpression/Ivs::tagRFPT None Inhibition of ciliary localization of
SmoM2::GFP
>30 >60
3T3/ SmoM2::GFP Overexpression/Shh-LightII None Inhibition of expression of Gli-
luciferase reporter induced by
SmoM2::GFP overexpression
>30 1.2
Cos7/Smo expression None Competition of BODIPY-
cyclopamine-Smo binding
0.1 >30
Ptch1+/− CGNP Shh Shh induced cell proliferation marked
by pH3
<0.625 <0.625
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